DOCSLIB.ORG

Coexistence of Different Phenotypes in a Family with Glucocorticoid-Remediable Aldosteronism

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Coexistence of Different Phenotypes in a Family with Glucocorticoid-Remediable Aldosteronism Journal of Human Hypertension (2004) 18, 47–51 & 2004 Nature Publishing Group All rights reserved 0950-9240/04 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism F Fallo1, C Pilon1, TA Williams2, N Sonino3, S Morra di Cella2, F Veglio2, R De Iasio4, P Montanari5 and P Mulatero2 1Department of Medical and Surgical Sciences, University of Padova, Italy; 2Department of Medicine and Experimental Oncology, University of Torino, Italy; 3Department of Statistical Sciences, University of Padova, Italy; 4CRBA, S Orsola Hospital, Bologna, Italy; 5City Hospital of Montecchio Emilia, Italy In glucocorticoid-remediable aldosteronism (GRA), activity. Sibling 1 was normotensive, normokalaemic there is a large interfamily variation of phenotype. We and had normal PRA and aldosterone. The father had report three subjects with GRA in a single family normal blood pressure and potassium, low-normal PRA (parents, two brothers and two sisters), of whom only and normal aldosterone. All three subjects had elevated one (proband) displayed classical features of the levels of urinary 18-hydroxycortisol and 18-oxocortisol. mineralocorticoid excess. The proband was a man Baseline 11-deoxycorticosterone (DOC), corticosterone found to be hypertensive and hypokalaemic at the age (B) and aldosterone were high in the proband and of 24 years. Plasma renin activity was suppressed and normal in the father and sibling 1; 11-deoxycortisol (S) plasma aldosterone was repeatedly elevated. Blood and cortisol (F) were normal. ACTH induced a normal pressure and aldosterone levels normalized within 5 increase of B, DOC, S and F, and an excessive days of dexamethasone therapy. The presence of a aldosterone increase in all three patients. Abnormalities chimaeric CYP11B1/CYP11B2 gene was demonstrated in the chimaeric portions of CYB11B1 or CYP11B2 genes by long-PCR and Southern blotting (crossover site at the did not account for the phenotypic disparity of the end of intron 3) in the proband, in the younger sister different members in a single GRA family. Altered (sibling 1) and in the father. In these patients, sequen- regulation of the chimaeric gene may be responsible cing of the chimaeric portion of CYP11B1 did not reveal for differences in its activity. any mutation, while sequencing of the chimaeric portion Journal of Human Hypertension (2004) 18, 47–51. of CYP11B2 showed a V386A polymorphism in exon 7, doi:10.1038/sj.jhh.1001636 known to cause only a minimal impairment of enzymatic Keywords: genotype; phenotype; glucocorticoid-remediable aldosteronism Introduction coid therapy.2,3 The genetic abnormality results from the inheritance of a hybrid gene derived from the Glucocorticoid-remediable aldosteronism (GRA) is a crossover between the 50-regulatory ACTH-respon- rare autosomal dominant disorder of adrenocortical sive sequence of the CYP11B1 (11b-hydroxylase) steroid synthesis, in which aldosterone secretion is gene and the 30-coding region of the CYP11B2 solely regulated by adrenocorticotropin (ACTH) 4 1 (aldosterone synthase) gene, and can be detected rather than angiotensin II. In the classical form, by a reliable and simple long-PCR test.5 A consider- this syndrome is characterized by hypokalaemia, able interfamily variation has been described for hyperaldosteronism and suppressed plasma renin many GRA phenotypic traits, including blood activity (PRA), presents at a young age in association pressure, aldosterone and PRA levels, hypokalaemia with familial occurrence of hypertension and cere- and occurrence of cerebrovascular accidents,2,3 and bral haemorrhage, and is correctable by glucocorti- no relationship between genotype and phenotype has been found.6,7 Scarce data are available on the intrafamily variation of phenotype in patients with Correspondence: Dr F Fallo, Department of Medical and Surgical genetically proved GRA. While in the family Sciences, University of Padova, Via Ospedale 105, 35128 Padova, previously reported by us8 and in that described Italy. 9 E-mail: [email protected] by Rich et al, the penetrance of hypertension and Received 12 May 2003; revised 5 August 2003; accepted 7 August aldosteronism was high in all affected pedigree 2003 members, in the family of Gates et al10 and in Different phenotypes in GRA F Fallo et al 48 another one more recently reported by us,11 the great 11-deoxycortisol (S) and cortisol (F) were normal. majority of affected members had mild hypertension ACTH administration induced a normal increase of and normal biochemistry, including serum potas- B, DOC, S and F, and an excessive increase of sium. Here we report a new family of six members in aldosterone. After 4 days of dexamethasone treat- which three subjects have been identified as ment (0.5 mg every 6 h) blood pressure decreased, possessing the same type of CYP11B1/CYP11B2 aldosterone fell to undetectable levels and serum chimaeric fusion, but display diverse biochemical potassium increased slightly. On a long-term basis, and clinical phenotypes. dexamethasone 0.250 mg/day in combination with nifedipine 10 mg t.i.d. controlled blood pressure and serum potassium levels. The presence of the Case reports chimaeric CYP11B1/CYP11B2 gene was demon- strated by long PCR and Southern blotting of The Proband genomic DNA. Sequencing of the chimaeric PCR product demonstrated that the crossover site was A 34-year-old man was referred to our centre for located at the end of intron 3, just before the evaluation of refractory hypertension. He had been beginning of exon 4. initially diagnosed with hypertension and hypo- kalaemia at 24 years of age. Primary aldosteronism was suspected on the basis of low PRA and elevated Family screening plasma and urinary aldosterone after repeated measurements. Abdominal CT scan and 75Se- All living first-degree family members were ana- methyl-nor-cholesterol adrenal scintiscan were in- lysed. The clinical, biochemical and genetic data are terpreted as showing adrenal bilateral hyperplasia, reported in Table 1. Body mass index (BMI) and and adrenal venous catheterization revealed sym- waist circumference were in the normal range for all metric, elevated secretion of aldosterone. The members, except the affected father and the un- patient had poorly controlled blood pressure for affected mother, who both showed mild overweight. many years while on multiple medical regimen, Blood pressure measurements and baseline data including spironolactone, calcium-channel blockers were obtained in the two parents and the three and ACE inhibitors. He was evaluated as an out- siblings (one brother and two sisters), evaluated as patient on an unrestricted sodium and potassium outpatients on an unrestricted sodium and potas- diet, and 3 weeks after withdrawal of antihyperten- sium diet. All siblings and the two parents were sive medications. There was no family history of found to be normotensive and normokalaemic, and hypertension or of early death from cerebrovascular had normal plasma and urinary aldosterone. The events. The proband’s blood pressure was 210/ father had low-normal PRA. No clinical conditions 110 mmHg, his serum potassium was 2.5 mmol/l, that could lower blood pressure, that is heart failure, upright PRA was suppressed and plasma and were present in the father. The father and the urinary aldosterone levels were elevated (Table 1). younger sister (ie, sibling 1) had high urinary 18- Routine biochemistry and renal scintigraphy were OHF and 18-oxoF. In these two subjects, an ACTH- normal. The EKG showed left ventricular hypertro- stimulation test was performed, following the same phy. Urinary levels of 18-hydroxycortisol (18-OHF) protocol described above. While baseline and and 18-oxocortisol (18-oxoF) were elevated. On a ACTH-stimulated plasma DOC, B, S and F were different day, ACTH 1-24 250 mg (Synacthen, Novar- normal, aldosterone was hyper-responsive to ACTH, tis Pharma) was injected as an i.v. bolus at 10.00 h as in the proband (Table 2). Sibling 1 and the father into the subject after a 30-min rest in a seated showed the same gene abnormality and the same position. Baseline 11-deoxycorticosterone (DOC), chimaeric gene crossover point of the proband. The corticosterone (B) and aldosterone were high, and crossover site was in the same region found in Table 1 Clinical, biochemical and genetic data of the family members Normal values Proband Sibling 1 Father Sibling 2 Sibling 3 Mother Age (years)/sex (M/F) 34/M 21/F 65/M 36/F 29/M 61/F BMI (kg/m2) o25 22 19 27 22 24 24 Waist circumference (cm) o102 Mo88 F 82 67 99 79 86 84 CYP11B1/CYP11B2 chimaeric gene Positive Positive Positive Negative Negative Negative Blood pressure (mmHg) o140/o90 210/110 125/80 140/80 120/85 120/70 135/85 Serum K (mmol/l) 3.5–5.0 2.5 4.3 4.0 4.4 4.4 4.2 Upr. PRA (ng/ml.h) 1.3–5.2 0.1 2.6 1.0 4.8 3.9 3.5 Upr. Aldosterone (pmol/l) 140–830 1166 510 338 624 680 416 Urinary aldosterone (nmol/day) 8–83 138.1 48.8 40.8 50.2 42.8 32.9 Urinary 18-OHF (mmol/day) 0.05–0.29 6.61 1.83 5.81 0.15 0.24 0.29 Urinary 18-oxoF (nmol/day) 0.5–3.9 234.0 42.5 161.7 2.9 2.1 3.2 Journal of Human Hypertension Different phenotypes in GRA F Fallo et al 49 Table 2 Plasma steroid levels in the three patients with GRA and normal controls before and after ACTH administration DOC (pmol/l) B (pmol/l) ALDO (pmol/l) S (nmol/l) F (nmol/l) Proband Baseline 966 11 268 747 0.96 310 ACTH 2719 88 876 2916 3.64 625 Sibling 1 Baseline 466 3112 238 1.05 376 ACTH 1933 49 835 1105 4.51 774 Father Baseline 370 3910 397 0.57 292 ACTH 1537 47 291 2391 2.88 727 Normal subjects (n=10)a Baseline 449 7 88 4148 7 1155 318 7 117 0.82 7 0.35 358 7 116 ACTH 1330 7 508 62 058 7 9866 735 7 314 4.10 7 1.33 877 7 174 DOC, 11-deoxycorticosterone; B, corticosterone; ALDO, aldosterone; S, 11-deoxycortisol; F, cortisol.
Load more

Recommended publications
  • Familial Hyperaldosteronism
    Familial hyperaldosteronism Description Familial hyperaldosteronism is a group of inherited conditions in which the adrenal glands, which are small glands located on top of each kidney, produce too much of the hormone aldosterone. Aldosterone helps control the amount of salt retained by the kidneys. Excess aldosterone causes the kidneys to retain more salt than normal, which in turn increases the body's fluid levels and blood pressure. People with familial hyperaldosteronism may develop severe high blood pressure (hypertension), often early in life. Without treatment, hypertension increases the risk of strokes, heart attacks, and kidney failure. Familial hyperaldosteronism is categorized into three types, distinguished by their clinical features and genetic causes. In familial hyperaldosteronism type I, hypertension generally appears in childhood to early adulthood and can range from mild to severe. This type can be treated with steroid medications called glucocorticoids, so it is also known as glucocorticoid-remediable aldosteronism (GRA). In familial hyperaldosteronism type II, hypertension usually appears in early to middle adulthood and does not improve with glucocorticoid treatment. In most individuals with familial hyperaldosteronism type III, the adrenal glands are enlarged up to six times their normal size. These affected individuals have severe hypertension that starts in childhood. The hypertension is difficult to treat and often results in damage to organs such as the heart and kidneys. Rarely, individuals with type III have milder symptoms with treatable hypertension and no adrenal gland enlargement. There are other forms of hyperaldosteronism that are not familial. These conditions are caused by various problems in the adrenal glands or kidneys. In some cases, a cause for the increase in aldosterone levels cannot be found.
    [Show full text]
  • Primary Aldosteronism: a Common Cause of Resistant Hypertension
    REVIEW CPD Primary aldosteronism: a common cause of resistant hypertension Gregory A. Kline MD, Ally P.H. Prebtani BScPhm MD, Alexander A. Leung MD, Ernesto L. Schiffrin CM MD PhD n Cite as: CMAJ 2017 June 5;189:E773-8. doi: 10.1503/cmaj.161486 esistant or difficult-to-control hypertension is a problem that may affect as many as 13% of all persons with hyper- KEY POINTS tension.1 It is estimated that more than 6 million (22.6%) • Difficult-to-control hypertension should trigger testing for primary Rof adults in Canada have hypertension, but less than two-thirds aldosteronism. have it adequately controlled despite conventional strategies for Measurement of aldosterone-to-renin ratio (ARR) is the preferred 2 • treatment. Uncontrolled hypertension may arise from nonadher- diagnostic test. ence to medication, selection of suboptimal treatment regimens • Patients with high ARR who are potential candidates for surgical and/or the presence of unidentified secondary causes. It is frus- adrenalectomy and those with severe hypertension for whom trating for both the patient and treating physician. Patients may discontinuation of antihypertensive drugs would be dangerous embark upon a series of variably successful approaches with dif- should be referred to a hypertension specialist for assessment. ferent drug classes. We review the accumulating epidemiologic • Patients with very severe hypertension who may not tolerate drug evidence on primary aldosteronism and hypertension that is adjustment for ARR measures should also be assessed by a hypertension specialist. resistant to treatment. We offer a pragmatic approach to diagno- sis for generalist physicians. Although no randomized controlled • Patients who cannot be considered for adrenalectomy may consider an empiric trial of spironolactone or eplerenone for blood pressure control.
    [Show full text]
  • Primary Aldosteronism—Not Just About Potassium and Blood Pressure
    QJM: An International Journal of Medicine, 2017, 175–177 doi: 10.1093/qjmed/hcw224 Advance Access Publication Date: 9 January 2017 Case report CASE REPORT Primary aldosteronism—not just about potassium and Downloaded from https://academic.oup.com/qjmed/article-abstract/110/3/175/2875723 by guest on 27 November 2019 blood pressure T.H. Toh, C.V. Tong and H.C. Chong From the Department of Internal Medicine, Malacca General Hospital, Malacca, Malaysia Address correspondence to T.H. Toh, Department of Internal Medicine, Malacca General Hospital, Malacca, Malaysia. email: [email protected] She presented again in the subsequent years with body Learning point for clinicians weakness, recurrent low electrolyte levels and was hyperten- sive. Gitelman or Bartter syndrome was considered initially due Primary aldosteronism is one of the few potentially cur- to certain overlapping features. The development of hyperten- able causes of hypertension and it requires a high index of suspicion in making an accurate diagnosis. This case sion later prompted the investigation for hyperaldosteronism. illustrates the importance of looking at electrolytes other Phaechromocytoma and Cushing’s syndrome were also ruled than just the potassium in a patient with severe primary out. We performed an aldosterone renin ratio, followed by a sa- aldosteronism. line suppression test. Patient was on prazosin and verapamil when these tests were carried out and had serum potassium >4 mmol/l with potassium supplements. Her laboratory results are in Table 1. Computed tomography of the adrenal showed a well defined Introduction hypodense lesion in the medial limb of the left adrenal gland Primary aldosteronism is a well established cause of secondary measuring 2.5 Â 1.6 Â 1.6 cm.
    [Show full text]
  • Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm
    Kidney360 Publish Ahead of Print, published on July 23, 2020 as doi:10.34067/KID.0000922020 Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm Michael R Lattanzio(1), Matthew R Weir(2) (1) Division of Nephrology, Department of Medicine, The Chester County Hospital/University of Pennsylvania Health System (2) Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD Correspondence: Matthew R Weir University of Maryland Medical Center Division of Nephrology 22 S. Greene St. Room N3W143 Baltimore, Maryland 21201 [email protected] 1 Copyright 2020 by American Society of Nephrology. Abbreviations PA=Primary Hyperaldosteronism CVD=Cardiovascular Disease PAPY=Primary Aldosteronism Prevalence in Hypertension APA=Aldosterone-Producing Adenoma BAH=Bilateral Adrenal Hyperplasia ARR=Aldosterone Renin Ratio AF=Atrial Fibrillation OSA=Obstructive Sleep Apnea OR=Odds Ratio AHI=Apnea Hypopnea Index ABP=Ambulatory Blood Pressure AVS=Adrenal Vein Sampling CT=Computerized Tomography MRI=Magnetic Resonance Imaging SIT=Sodium Infusion Test FST=Fludrocortisone Suppression Test CCT=Captopril Challenge Test PAC=Plasma Aldosterone Concentration PRA=Plasma Renin Activity MRA=Mineralocorticoid Receptor Antagonist MR=Mineralocorticoid Receptor 2 Abstract Nearly seven decades have elapsed since the clinical and biochemical features of Primary Hyperaldosteronism (PA) were described by Conn. PA is now widely recognized as the most common form of secondary hypertension. PA has a strong correlation with cardiovascular disease and failure to recognize and/or properly diagnose this condition has profound health consequences. With proper identification and management, PA has the potential to be surgically cured in a proportion of affected individuals. The diagnostic pursuit for PA is not a simplistic endeavor, particularly since an enhanced understanding of the disease process is continually redefining the diagnostic and treatment algorithm.
    [Show full text]
  • High and Non-Suppressible Plasma Renin Activity in a Patient with Aldosterone Producing Adenoma: Pathophysiologic and Diagnostic Implications
    Journal of Human Hypertension (1999) 13, 75–78 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh CASE REPORT High and non-suppressible plasma renin activity in a patient with aldosterone producing adenoma: pathophysiologic and diagnostic implications E Shyong Tai and PHK Eng Department of Endocrinology, Singapore General Hospital, Singapore We describe a case of primary aldosteronism due to an possible pathophysiological causes of a rise in PRA in aldosterone producing adenoma with high and non-sup- this clinical setting and suggest that underlying arteri- pressible plasma renin activity (PRA). She had sup- olar disease due to prolonged hypertension may be the pressed PRA at initial diagnosis. This rose above the cause of increased and non-suppressible PRA in pri- reference range for normal individuals over a period of mary aldosteronism. 7 years with untreated hypertension. We discuss the Keywords: primary aldosteronism; plasma renin activity; diagnosis Introduction Case report Primary aldosteronism is classically associated with Our patient was a 34-year-old woman who was hypertension, hypokalaemia and suppressed plasma found to have hypertension during the fifteenth renin activity (PRA). Most cases are due to an aldo- week of pregnancy. Plasma aldosterone was sterone producing adenoma (APA). We present a 2039 pmol/l, PRA Ͻ0.15 ␮g/l/h and a diagnosis of case of prolonged, untreated, primary aldosteronism primary aldosteronism was made. Following the due to an APA. She had suppressed PRA at the time delivery of her child, she defaulted follow-up and of diagnosis, which became elevated and non-sup- was not treated with any antihypertensives nor pot- pressible by intravenous salt loading.
    [Show full text]
  • A Case of Gitelman's Syndrome with Decreased Angiotensin II–Forming Activity
    545 Hypertens Res Vol.29 (2006) No.7 p.545-549 Case Report A Case of Gitelman’s Syndrome with Decreased Angiotensin II–Forming Activity Kimika ETO1), Uran ONAKA1), Takuya TSUCHIHASHI1), Takashi HIRANO2), Masaru NAKAYAMA2), Kosuke MASUTANI3), Hideki HIRAKATA3), Hidenori URATA4), and Minoru YASUJIMA5) Gitelman’s syndrome (GS) is a variant of Bartter’s syndrome (BS) characterized by hypokalemic alkalosis, hypomagnesemia, hypocalciuria and secondary aldosteronism without hypertension. A 31-year old Japa- nese man who had suffered from mild hypokalemia for 10 years was admitted to our hospital. He had met- abolic alkalosis, hypokalemia and hypocalciuria. Since he had two missense mutations (R261C and L623P) in the thiazide-sensitive Na-Cl cotransporter (TSC) gene (SLC12A3), he was diagnosed as having GS. He showed hyperreninism and a high angiotensin I (Ang I) level, whereas his angiotensin II (Ang II) and aldo- sterone levels were not elevated. His angiotensin converting enzyme (ACE) activities were normal, and administration of captopril inhibited the production of Ang II and aldosterone. We evaluated the Ang II–form- ing activity (AIIFA) of other enzymes in his lymphocytes. Interestingly, chymase-dependent AIIFA was not detected in the lymphocytes. Together, these results suggest that the lack of chymase activity resulted in the manifestation of GS without hyperaldosteronism. (Hypertens Res 2006; 29: 545–549) Key Words: Gitelman’s syndrome, angiotensin II, aldosterone, chymase several TSC gene mutations have been reported (5–10). Introduction Moreover, GS is characterized by sodium wasting, low blood pressure, and secondary hyperaldosteronism. Here, we report In 1966, Gitelman et al. reported three adult patients with a case of GS with hyperreninism and high angiotensin I (Ang intermittent episodes of muscle weakness and tetany, I) but without elevated angiotensin II (Ang II) or hyperaldos- hypokalemia, and hypomagnesemia, but no history of poly- teronism.
    [Show full text]
  • Reduced Na+,K+-Atpase Activity in Patients with Pseudohypoaldosteronism
    0031-399819413503-0372$03.00/0 PEDIATRIC RESEARCH Vol. 35, No. 3. 1994 Copyright O 1994 International Pediatric Research Foundation, Inc. Prinrc7d in U.S. A. Reduced Na+,K+-ATPase Activity in Patients with Pseudohypoaldosteronism TZW BISTRITZER, SANDRA EVANS, DITA COTARIU, MICHAEL GOLDBERG, AND MORDECHAI ALADJEM Departments of Pediatrics [T.B., hf.A.1, Bioche~nicalPathology [S.E., D.C.], and Neonatology [Jf.G.], Assaf Harofeh hfedical Center, Sackler Faclclty ofhfedicine, TeI Aviv University, Zerfi~i70300. Israel ABSTRACT. Pseudohypoaldosteronism is a hereditary wasting syndrome varies widely with age and is particularly salt-wasting syndrome usually seen in infancy with weight severe in infancy. Spontaneous improvement in sodium conser- loss, dehydration, and failure to thrive. The patho- vation occurs as the individuals become older. Aldosterone de- physiologic origin of pseudohypoaldosteronism is un- ficiency in the face of overproduction of zona glomerulosa 18- known. The defect could be related to the unresponsiveness hydroxycorticosterone (10) was found, an abnormality for which of target organs to mineralocorticoids resulting in hypo- the term type 2 corticosterone methyl-oxidase defect was coined natremia, hyperkalemia, and markedly elevated plasma (1 1). Treatment with mineralocorticoids and high-sodium diet aldosterone and renin levels. Red blood cell Na+,K+-ATP reduces the secretion of the aldosterone precursor, restores elec- ase activity was measured in a pair of twins with pseudo- trolyte balance, and normalizes the growth rate (3). hypoaldosteronism, in an unrelated child with hypoaldos- Little information has been added in regard to the patho- teronism, and in an age-matched group of 50 healthy physiologic expression of PHA since its original description by infants and young children.
    [Show full text]
  • Primary Aldosteronism, a Common Entity? the Myth Persists
    Journal of Human Hypertension (2002) 16, 159–162 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh REVIEW ARTICLE Primary aldosteronism, a common entity? the myth persists PL Padfield Department of Medical Sciences, Western General Hospital, University of Edinburgh, Scotland, UK Primary aldosterone excess or hyperaldosteronism is aldosterone is in fact inappropriately elevated if the an important cause of hypertension which, when asso- renin level is low. A single measurement of the ratio of ciated with an aldosterone secreting adenoma, is amen- aldosterone to renin levels is claimed to be highly pre- able to surgical cure. The biochemical hallmarks of the dictive of patients who will have primary aldosterone condition are a relative excess of aldosterone pro- excess. This paper examines the logic behind such duction with suppression of plasma levels of renin (a claims and presents evidence from the literature that an proxy for angiotensin II, the major trophic substance abnormal ratio is simply a different description of the regulating aldosterone secretion). This combination of low renin state and that such patients do not necessarily a high aldosterone and a low renin is however more have mineralocorticoid hypertension. Most patients ‘dis- commonly associated with ‘nodular hyperplasia’ of the covered’ by this test will have what many call low-renin adrenal glands, a condition not improved by surgery hypertension, a condition not amenable to specific ther- and variably responsive to the effects of the mineral- apy. Claims that they are peculiarly sensitive to the ocorticoid antagonist, spironolactone. Until recently the hypotensive effects of spironolactone have not been prevalence of either form of secondary hypertension tested in controlled trials.
    [Show full text]
  • Primary Hyperaldosteronism: a Case of Unilateral Adrenal Hyperplasia with Contralateral Incidentaloma Sujit Vakkalanka,1 Andrew Zhao,1 Mohammed Samannodi2
    Unexpected outcome (positive or negative) including adverse drug reactions CASE REPORT Primary hyperaldosteronism: a case of unilateral adrenal hyperplasia with contralateral incidentaloma Sujit Vakkalanka,1 Andrew Zhao,1 Mohammed Samannodi2 1University at Buffalo, Buffalo, SUMMARY palpitations or any difficulty breathing in the past. New York, USA Primary hyperaldosteronism is one of the most common She was being managed in an outpatient setting for 2Department of Medicine, Buffalo, New York, USA causes of secondary hypertension but clear hypokalaemia and hypertension since 2009. She differentiation between its various subtypes can be a has been taking three antihypertensives (amlodi- Correspondence to clinical challenge. We report the case of a 37-year-old pine, benazepril and labetalol) and supplemental Dr Mohammed Samannodi, African-American woman with refractory hypertension potassium (2 tablets of 10 mEq three times a day) [email protected] who was admitted to our hospital for palpitations, but was very recently switched to hydralazine, ver- Accepted 28 June 2016 shortness of breath and headache. Her laboratory results apamil and doxazosin mesylate, and two potassium showed hypokalaemia and an elevated aldosterone/renin tablets of 20 mEq three times a day. ratio. An abdominal CT scan showed a nodule in the left On physical examination, her heart rate was adrenal gland but adrenal venous sampling showed 110 bpm while the blood pressure was 170/ elevated aldosterone/renin ratio from the right adrenal 110 mm Hg. Cardiac, abdominal, neurological and vein. The patient began a new medical regimen but musculoskeletal examinations were unimpressive declined any surgical options. We recommend with no signs of clubbing or oedema.
    [Show full text]
  • Monogenic Forms of Mineralocorticoid Hypertension: Insights Into the Pathogenesis of ‘Essential’ Hypertension?
    Journal of Human Hypertension (1998) 12, 7–12 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 REVIEW ARTICLE Monogenic forms of mineralocorticoid hypertension: insights into the pathogenesis of ‘essential’ hypertension? M Petrelli and PM Stewart Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK Keywords: hyperaldosteronism; mineralocorticoid; Liddle’s syndrome; inheritance; cortisol; 11␤-hydroxysteroid dehydrogen- ase Hypertension is a common condition, which, mary aldosteronism due to an adrenocortical tumour depending on its definition, affects 10–25% of the (Conn’s Syndrome).1 Both subjects had a mineral- population. Because it is an established risk factor ocorticoid excess syndrome, characterised by pot- for coronary and cerebrovascular disease, hyperten- assium deficiency, suppressed plasma renin activity sion has, quite rightly, been targeted as an important (PRA) and increased aldosterone secretion rate, factor in determining the health of the nation. which, in contrast to tumorous aldosteronism, Despite this we can explain the underlying cause of responded to treatment with the synthetic glucocort- a patient’s hypertension in Ͻ5% of cases; the icoid, dexamethasone. Shortly afterwards, an remainder are labelled ‘essential’ hypertension, an additional, well-documented case was described, elegant way of stating that the aetiology is unknown. confirming the existence of this new ‘glucocorticoid As a result, in the vast majority of cases treatment remediable’ aldosteronism syndrome.2 Sub- is given on an empirical basis. sequently it was shown to be inherited in an autoso- In the last 5 years, significant advances have been mal dominant fashion and approximately 100 cases made in our understanding of the pathogenesis of were reported in the world literature up to the early hypertension with the characterisation of three 1990’s.3–9 forms of inherited hypertension.
    [Show full text]
  • Prevalence of Primary Hyperaldosteronism Assessed by Aldosterone/Renin Ratio and Spironolactone Testing
    I ORIGINAL PAPERS Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing Sue Hood, John Cannon, Roger Foo and Morris Brown ABSTRACT – Recent studies have suggested that Aldosterone-secreting adenomas were long consid- Sue Hood RGN primary hyperaldosteronism may be present in ered a rare cause of hypertension, with bilateral Research Sister more than 10% of patients with hypertension. We micronodular hyperplasia accounting for a similarly *John Cannon MB aimed to estimate the prevalence in unselected small proportion – less than 2% – of all hyperten- FRCGP General patients in primary care, and investigate the sion.1 But recent studies have suggested that primary Practitioner influence of current drug treatment upon the hyperaldosteronism (PHA) may be present in at least Roger Foo MD aldosterone/renin ratio (ARR) and its prediction 10% of patients.2–5 These studies have used biochem- MRCP Specialist of blood pressure response to spironolactone. We ical measures of autonomous aldosterone secretion, Registrar measured blood pressure, plasma electrolytes, usually the ratio of plasma aldosterone to renin and Morris Brown MSc renin activity and aldosterone in 846 patients the failure of aldosterone to suppress during treat- MD FRCP FMedSci, Professor of with hypertension. Spironolactone 50 mg was ment with salt supplementation. However, as often Clinical prescribed for one month to patients with blood occurs when the arbiter for diagnosis changes – here, Pharmacology pressure ≥130/85 mmHg and ARR ≥400. The from anatomical to biochemical – the question arises primary outcome measure was to discover the whether the definition of the condition has also Clinical Pharmacology Unit, proportion of patients with plasma aldosterone changed.
    [Show full text]
  • Pseudo Bartter Syndrome from Surreptitious Purging Behaviour In
    al Dis ion ord rit e t rs u N & f T o h Gentile, J Nutr Disorders Ther 2012, 2:1 l e a r n a r DOI: 10.4172/2161-0509.1000107 p u y o Journal of Nutritional Disorders & Therapy J ISSN: 2161-0509 Case Report Open Access Pseudo Bartter Syndrome from Surreptitious Purging Behaviour in Anorexia Nervosa Maria Gabriella Gentile* Eating Disorder Unit, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20126 Milan, Italy Abstract Pseudo Bartter syndrome is a rare disorder characterized by metabolic alkalosis, hypokalaemia, hyperaldosteronism, hyperreninism, normal blood pressure and hyperplasia of the juxtaglomerular apparatus. The most dangerous complication of Pseudo Bartter syndrome is hypokalemia. Hypokalemia caused by vomiting, diarrhea, prolonged fasting, abuse of potassium-depleting drugs, may be present in patients with binge /purging form of anorexia or bulimia nervosa. We report a case of a 19-year-old girl with anorexia nervosa (BMI 16.15 kg/m2) and severe prolonged hypokalemia (1.9 mEq/l), metabolic alkalosis and severe protracted secondary hyperaldosteronism (i.e. Pseudo Bartter’s syndrome) from surreptitious purging behaviour (vomit and laxative abuse). An intensive multidisciplinary day-hospital treatment including long-term potassium supplementation, a potassium- sparing diuretic was necessary to resolve the case and to allow the young girl to admit her previous purging behaviour and after three months to get at a normal kalemia without any potassium supplementation and BMI at a normal value (20 kg/m2). Given the dangers to the heart electrical and mechanical functions set by severe potassium deficiency, it is mandatory to find out the true cause so that a proper treatment can be started.
    [Show full text]